Astellas Pharma Inc (4503.T)

4503.T on Tokyo Stock Exchange

1,901JPY
27 Feb 2015
Change (% chg)

¥3 (+0.16%)
Prev Close
¥1,898
Open
¥1,900
Day's High
¥1,933
Day's Low
¥1,894
Volume
7,628,900
Avg. Vol
7,275,612
52-wk High
¥1,933
52-wk Low
¥1,062

4503.T

Chart for 4503.T

About

Astellas Pharma Inc. is a Japan-based company mainly engaged in the pharmaceutical business. The Company is involved in the manufacture and sale of pharmaceutical products in Japan, the United States, Europe, China, Korea and Taiwan, through its subsidiaries. Its main products include immunosuppressive drug Prograf, overactive... (more)

Overall

Beta: 0.58
Market Cap(Mil.): ¥4,289,145.00
Shares Outstanding(Mil.): 2,259.82
Dividend: 16.00
Yield (%): 1.48

Financials

  4503.T Industry Sector
P/E (TTM): 33.87 38.91 40.13
EPS (TTM): 56.04 -- --
ROI: 9.36 17.02 16.31
ROE: 9.80 17.54 17.28
Search Stocks

REFILE-TABLE-Astellas -9-MTH group results (IFRS)

(Operating forecast is core operating forecast, EPS forecast is core EPS forecast.) Feb 2 - Astellas Pharma Inc. CONSOLIDATED FINANCIAL HIGHLIGHTS (in billions of yen unless specified) 9 months ended 9 months ended Year to Dec 31, 2014 Dec 31, 2013 Mar 31, 2015 LATEST YEAR-AGO COMPANY RESULTS RESULT FOREC

02 Feb 2015

FDA panel backs Astellas drug for invasive fungal infections

- A panel of experts on Thursday voted to recommend that U.S. health regulators approve Astellas Pharma Inc's drug for the treatment of rare, often fatal invasive fungal infections that can target patients with blood cancers.

22 Jan 2015

UPDATE 1-FDA panel backs Astellas drug for invasive fungal infections

Jan 22 - A panel of experts on Thursday voted to recommend that U.S. health regulators approve Astellas Pharma Inc's drug for the treatment of rare, often fatal invasive fungal infections that can target patients with blood cancers.

22 Jan 2015

BRIEF-Astellas announces end of license agreement with Janssen Biotech

* Announces end of license agreement with janssen biotech to develop oral janus kinase inhibitor

02 Dec 2014

CORRECTED-UPDATE 2-Dendreon files for bankruptcy as cancer vaccine disappoints

(Corrects paragraph 6 to say Xtandi is marketed by Medivation and Astellas)

10 Nov 2014

REFILE-TABLE-Astellas -6-MTH group results (IFRS)

(Operating forecast is core operating forecast, EPS forecast is core EPS forecast.Adds core net profit) Oct 31 - Astellas Pharma Inc. CONSOLIDATED FINANCIAL HIGHLIGHTS (in billions of yen unless specified) 6 months ended 6 months ended Year to Sep 30, 2014 Sep 30, 2013 Mar 31, 2015 LATEST YEAR-AGO COMPANY RESULTS

31 Oct 2014

U.S. FDA approves expanded use of Medivation prostate cancer drug

- U.S. health regulators approved the use of Medivation Inc's and Astellas Pharma Inc's advanced prostate cancer drug Xtandi in men who have not yet received chemotherapy, the companies said on Wednesday, significantly expanding the potential patient population for the oral medicine.

10 Sep 2014

UPDATE 1-U.S. FDA approves expanded use of Medivation prostate cancer drug

Sept 10 - U.S. health regulators approved the use of Medivation Inc's and Astellas Pharma Inc's advanced prostate cancer drug Xtandi in men who have not yet received chemotherapy, the companies said on Wednesday, significantly expanding the potential patient population for the oral medicine.

10 Sep 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
£10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks